Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Case series suggests biologics, JAK inhibitors safe during pandemic

Key clinical point: Use of biologics and Janus kinase inhibitors was not associated with worse outcomes in 86 people with inflammatory diseases who contracted COVID-19.

Major finding: Overall, 14 patients (16%) were hospitalized with COVID-19, which is consistent the 26% hospitalization rate among the general population in New York City.

Study details: A case series with 86 subjects

Disclosures: There was no external funding. The study lead reported ties to Janssen, and the senior author ties to that and other companies.


Haberman R et al. N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567.